age1✓

Luke Martin @VentureCoinist

A conversation with Dr. Alex Colville (@AlexJColville), co-founder and GP of Age1, the first longevity fund. He studied the biology of aging for his PhD in Genetics at Stanford and has deployed more than $100M into longevity and biotech. We discuss how Anthropic & OpenAi are suddenly buying biotech startups and racing to solve Ai drug discovery. And why tech billionaires + crypto founders are both allocating significant capital to this sector. Enjoy! 00:00 Intro 01:45 Chatgpt Moment for Biotech 03:57 Why Longevity Is Exploding Now 07:33 Exciting Bio Investment Areas 11:09 Growing Fresh Cells From Stem Cells 16:07 Epigenetic Reprogramming 19:50 Sponsored by Kraken 20:56 Reversible Cryopreservation 22:56 NewLimit's Big Bet 28:15 Is There One Cure? 30:10 Peptides Real or Hype? 34:30 What AI Is Unlocking in Biotech 36:54 Zero-Person Biotech? 40:35 Ai Labs Becoming Biotechs 44:06 Open Source vs Secrecy 47:18 Crypto Founders Longevity Bets 50:05 The Story Behind Age1 55:30 Moonshots 1:00:55 Dogs Living Forever 1:03:31 Manhattan Project for Aging 1:06:38 Contrarian Biotech 1:09:07 Holy Grail Bet

age1 @age1vc

Last week, age1 Partner @satvik_93 shared the stage with @BrackLab (Program Director, @ARPA_H), @JamesPeyer (CEO, @CambrianBio), Mike Cooney (Vice President, @BainCapital), and @Jack_O_Meara (CEO at our portfolio company @aerskatx) to discuss how to break into longevity biotech. The panel took on two questions. First, how can pharma companies truly begin to develop therapeutics targeted towards healthy longevity and prevention? Next, how can early talent and specialists in adjacent areas like AI and bioengineering begin to make their mark on the field? Much of the conversation focused on practical ways to reach broader patient populations and intervene earlier in progressive conditions of aging like dementia (@aerskatx) and metabolic decline. One area we're especially excited about is muscle, tendon, and joint health, where we expect a lot of new drug development over the next five years. If you're working on this, we'd love to talk. Thanks to @sufaldeb (@NornGroup) for organizing and bringing together an amazing group of founders, early talent, and strategists.

age1 @age1vc

Last week, age1 Partner @satvik_93 shared the stage with @BrackLab (Program Director, @ARPA_H), @JamesPeyer (CEO, @CambrianBio), Mike Cooney (Vice President, @BainCapital), and @Jack_O_Meara (CEO at our portfolio company @aerskatx) to discuss how to break into longevity biotech. The panel took on two questions. First, how can pharma companies truly begin to develop therapeutics targeted towards healthy longevity and prevention? Next, how can early talent and specialists in adjacent areas like AI and bioengineering begin to make their mark on the field? Much of the conversation focused on practical ways to reach broader patient populations and intervene earlier in progressive conditions of aging like dementia (@aerskatx) and metabolic decline. One area we're especially excited about is muscle, tendon, and joint health, where we expect a lot of new drug development over the next five years. If you're working on this, we'd love to talk. Thanks to @sufaldeb (@NornGroup) for organizing and bringing together an amazing group of founders, early talent, and strategists.

Regeneron @Regeneron

Today the U.S. FDA approved our medicine – the first and only gene therapy for genetic #hearingloss – signaling a new era where enabling 24/7 natural hearing is now possible. We are proud to make this available for free in the U.S. Read more:

Alex Colville @AlexJColville

AGI timelines are accelerating dramatically. The promise of many working in the field is the ultimate health impact to humanity including cures to cancer and significantly increasing healthy lifespan. But how? Join the first Summit on the Convergence of AI and Longevity!

Loyal @loyalfordogs

We’re excited to share we’ve raised $100M in Series C funding, bringing our total investment to over $250M. Led by @age1vc with participation from @BaillieGifford and existing investors, this funding will help us move from late-stage development to market readiness for LOY-002.

Matthew Herper @matthewherper

Biotech doubles financing in quest to silence genes behind neurological diseases via @statnews

Lynetta Wang @LynettaWang126

“Biology is hard”, betting on it is harder. Launching the first piece of a 5-part series for founders & scientists trying to find “the” successful target: Big thanks to @age1vc crew - genuinely fun building this:)